IQVIA Holdings Inc (IQV)

NYSE
Currency in USD
137.00
-1.04(-0.75%)
Closed·
After Hours
137.75+0.75(+0.55%)
·
IQV Scorecard
Full Analysis
Management has been aggressively buying back shares
Trading near 52-week Low
Fair Value
Day's Range
134.65137.88
52 wk Range
134.65252.88
Key Statistics
Edit
Prev. Close
138.04
Open
135.96
Day's Range
134.65-137.88
52 wk Range
134.65-252.88
Volume
2.25M
Average Vol. (3m)
2.13M
1-Year Change
-39.67%
Book Value / Share
33.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IQV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
193.97
Upside
+41.59%
Members' Sentiments
Bearish
Bullish
ProTips
15 analysts have revised their earnings downwards for the upcoming period
Show more

IQVIA Holdings Inc Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

IQVIA Holdings Inc SWOT Analysis


Future Growth Outlook
Delve into IQVIA's long-range plan projecting 6-9% growth, balancing near-term challenges with innovative solutions in decentralized clinical trials
Strategic Partnerships
Explore IQVIA's collaboration with NVIDIA, enhancing AI capabilities to potentially transform clinical research and drug development processes
Financial Resilience
Despite industry headwinds, IQVIA maintains a strong financial health score of 2.75, with analyst price targets ranging from $205 to $270
Data-Driven Leade
IQVIA, the largest global CRO, leverages proprietary data and AI to revolutionize drug development and commercialization in over 100 countries
Read full SWOT analysis

IQVIA Holdings Inc Earnings Call Summary for Q1/2025

  • IQVIA beats Q1 2025 forecasts: EPS $2.70 vs $2.64 expected, revenue $3.83B vs $3.78B projected; stock dips 0.82% pre-market
  • Revenue up 2.5% YoY, adjusted EPS rises 6.3%; company raises full-year revenue guidance to $16.0-$16.4B
  • Strong free cash flow of $426M; company continues strategic acquisitions and share repurchases
  • CEO expresses confidence in navigating market uncertainties; emphasis on scaling AI deployments and expanding partnerships
  • Analysts maintain 'Buy' recommendation despite 6 downward earnings revisions; InvestingPro suggests stock undervalued at P/E 20.2x
Last Updated: 05/06/2025, 10:55 AM
Read Full Transcript

Compare IQV to Peers and Sector

Metrics to compare
IQV
Peers
Sector
Relationship
P/E Ratio
17.8x13.6x−0.4x
PEG Ratio
68.540.070.00
Price / Book
4.0x1.4x2.6x
Price / LTM Sales
1.5x1.5x2.9x
Upside (Analyst Target)
36.1%110.0%51.7%
Fair Value Upside
Unlock35.8%9.5%Unlock

Analyst Ratings

17 Buy
7 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 193.97
(+41.59% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
2.70 / 2.64
Revenue / Forecast
3.83B / 3.78B
EPS Revisions
Last 90 days

People Also Watch

23.98
YOU
-5.70%
284.21
ZBRA
-1.44%
588.34
REGN
-1.43%
99.89
CRUS
-2.24%
295.57
UNH
-0.37%

FAQ

What Is the IQVIA Holdings (IQV) Stock Price Today?

The IQVIA Holdings stock price today is 137.00

What Stock Exchange Does IQVIA Holdings Trade On?

IQVIA Holdings is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for IQVIA Holdings?

The stock symbol for IQVIA Holdings is "IQV."

What Is the IQVIA Holdings Market Cap?

As of today, IQVIA Holdings market cap is 23.70B.

What Is IQVIA Holdings's Earnings Per Share (TTM)?

The IQVIA Holdings EPS (TTM) is 7.42.

When Is the Next IQVIA Holdings Earnings Date?

IQVIA Holdings will release its next earnings report on Jul 29, 2025.

From a Technical Analysis Perspective, Is IQV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has IQVIA Holdings Stock Split?

IQVIA Holdings has split 0 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.